Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: CTS001
MIFTS: 65

Cutis Laxa

Categories: Blood diseases, Bone diseases, Cardiovascular diseases, Eye diseases, Fetal diseases, Gastrointestinal diseases, Genetic diseases, Mental diseases, Metabolic diseases, Muscle diseases, Nephrological diseases, Neuronal diseases, Rare diseases, Skin diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Cutis Laxa

About this section

MalaCards integrated aliases for Cutis Laxa:

Name: Cutis Laxa 12 74 52 25 58 36 29 54 6 43 15 71
Generalized Elastolysis 52 71
Cutis Laxa Syndrome 6
Dermatomegaly 25
Dermatolysis 25
Loose Skin 12

Characteristics:

Orphanet epidemiological data:

58
cutis laxa
Inheritance: Autosomal dominant,Autosomal recessive,Not applicable,X-linked recessive; Prevalence: 1-9/1000000 (Europe);

Classifications:

MalaCards categories:
Global: Rare diseases Fetal diseases Genetic diseases Metabolic diseases
Anatomical: Skin diseases Neuronal diseases Eye diseases Cardiovascular diseases Bone diseases Gastrointestinal diseases Nephrological diseases Muscle diseases Blood diseases Mental diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare skin diseases
Developmental anomalies during embryogenesis


Sources

Summaries for Cutis Laxa

About this section
Genetics Home Reference : 25 Cutis laxa is a disorder of connective tissue, which is the tissue that forms the body's supportive framework. Connective tissue provides structure and strength to the muscles, joints, organs, and skin. The term "cutis laxa" is Latin for loose or lax skin, and this condition is characterized by skin that is sagging and not stretchy (inelastic). The skin often hangs in loose folds, causing the face and other parts of the body to have a droopy appearance. Extremely wrinkled skin may be particularly noticeable on the neck and in the armpits and groin. Cutis laxa can also affect connective tissue in other parts of the body, including the heart, blood vessels, joints, intestines, and lungs. The disorder can cause heart problems and abnormal narrowing, bulging, or tearing of critical arteries. Affected individuals may have soft out-pouchings in the lower abdomen (inguinal hernia) or around the belly button (umbilical hernia). Pouches called diverticula can also develop in the walls of certain organs, such as the bladder and intestines. During childhood, some people with cutis laxa develop a lung disease called emphysema, which can make it difficult to breathe. Depending on which organs and tissues are affected, the signs and symptoms of cutis laxa can range from mild to life-threatening. Researchers have described several different forms of cutis laxa. The forms are often distinguished by their pattern of inheritance: autosomal dominant, autosomal recessive, or X-linked. In general, the autosomal recessive forms of cutis laxa tend to be more severe than the autosomal dominant forms. In addition to the features described above, some people with autosomal recessive cutis laxa have delayed development, intellectual disability, seizures, and problems with movement that can worsen over time. The X-linked form of cutis laxa is often called occipital horn syndrome. This form of the disorder is considered a mild type of Menkes syndrome, which is a condition that affects copper levels in the body. In addition to sagging and inelastic skin, occipital horn syndrome is characterized by wedge-shaped calcium deposits in a bone at the base of the skull (the occipital bone), coarse hair, and loose joints.

MalaCards based summary : Cutis Laxa, also known as generalized elastolysis, is related to acquired cutis laxa and cutis laxa, autosomal recessive, type iiib, and has symptoms including pruritus An important gene associated with Cutis Laxa is PYCR1 (Pyrroline-5-Carboxylate Reductase 1), and among its related pathways/superpathways are Degradation of the extracellular matrix and Ion channel transport. The drugs Phylloquinone and fluindione have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and lung, and related phenotypes are inguinal hernia and short stature

Disease Ontology : 12 A skin disease characterized by loose, hanging, wrinkled skin lacking in elasticity.

NIH Rare Diseases : 52 Cutis laxa is a connective tissue disorder characterized by skin that is sagging and not stretchy. The skin often hangs in loose folds, causing the face and other parts of the body to have a droopy appearance. Cutis laxa can also affect connective tissue in other parts of the body, including the heart, blood vessels, joints, intestines, and lungs. Depending on which organs and tissues are affected, the signs and symptoms can range from mild to life-threatening. It may be acquired or inherited . The different forms of inherited cutis laxa are distinguished by their pattern of inheritance: autosomal dominant , autosomal recessive , or X-linked . In general, the autosomal recessive forms tend to be more severe than the autosomal dominant form. The X-linked form of cutis laxa is often called occipital horn syndrome .

KEGG : 36 Cutis laxa is a heterogeneous group of connective tissue disorders with variable organ involvement. The most obvious symptom of cutis laxa is loose and sagging skin due to reduced elastic fibers in the dermis. The phenotype of autosomal recessive cutis laxa II includes abnormal growth, developmental delay, and associated skeletal abnormalities. Autosomal recessive cutis laxa III, also known as De Barsy syndrome, is characterized by an aged appearance with distinctive facial features, sparse hair, ophthalmologic abnormalities, and intrauterine growth retardation.

Wikipedia : 74 Cutis laxa or pachydermatocele is a group of rare connective tissue disorders in which the skin becomes... more...

Sources

Related Diseases for Cutis Laxa

About this section

Diseases in the Cutis Laxa family:

Cutis Laxa, Autosomal Dominant 1 Cutis Laxa, Autosomal Recessive, Type Ia
Cutis Laxa, Autosomal Recessive, Type Iiia Cutis Laxa, Autosomal Recessive, Type Iia
Cutis Laxa, Autosomal Recessive, Type Iib Cutis Laxa, Autosomal Recessive, Type Ic
Cutis Laxa, Autosomal Dominant 2 Cutis Laxa, Autosomal Recessive, Type Ib
Cutis Laxa, Autosomal Recessive, Type Iiib Cutis Laxa, Autosomal Dominant 3
Cutis Laxa, Autosomal Recessive, Type Iic Cutis Laxa, Autosomal Recessive, Type Iid
Autosomal Recessive Cutis Laxa Type Iii Autosomal Recessive Cutis Laxa Type I
Atp6v0a2-Related Cutis Laxa Efemp2-Related Cutis Laxa
Fbln5-Related Cutis Laxa Ltbp4-Related Cutis Laxa
Acquired Cutis Laxa Autosomal Recessive Cutis Laxa Type 2

Diseases related to Cutis Laxa via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 325)
# Related Disease Score Top Affiliating Genes
1 acquired cutis laxa 34.8 FBLN5 ELN
2 cutis laxa, autosomal recessive, type iiib 34.8 PYCR1 LTBP4 GORAB EFEMP2 ATP6V0A2 ALDH18A1
3 cutis laxa, autosomal recessive, type iiia 34.7 RIN2 PYCR1 LTBP4 GORAB EFEMP2 ATP6V0A2
4 fbln5-related cutis laxa 34.7 FBLN5 ELN
5 cutis laxa, autosomal dominant 1 34.6 GGCX FBN1 FBLN5 ELN EFEMP2 ALDH18A1
6 cutis laxa, autosomal recessive, type iid 34.6 RIN2 LTBP4 GORAB ATP6V1E1 ATP6V1A ATP6V0A2
7 cutis laxa, autosomal recessive, type ic 34.6 RIN2 PYCR1 LTBP4 GORAB FBLN5 EFEMP2
8 cutis laxa, autosomal recessive, type iib 34.6 RIN2 PYCR1 LTBP4 GORAB FBLN5 EFEMP2
9 cutis laxa, autosomal recessive, type iia 34.5 RIN2 PYCR1 LTBP4 GORAB FBLN5 EFEMP2
10 cutis laxa, autosomal recessive, type ib 34.5 RIN2 PYCR1 LTBP4 GORAB FBLN5 EFEMP2
11 autosomal recessive cutis laxa type iii 34.4 RIN2 PYCR1 LTBP4 GORAB FBLN5 EFEMP2
12 macs syndrome 34.0 RIN2 FBLN5
13 autosomal recessive cutis laxa type i 34.0 RIN2 PYCR1 LTBP4 GORAB FBN1 FBLN5
14 cutis laxa, autosomal recessive, type ia 33.9 RIN2 PYCR1 LTBP4 LOXL1 GORAB FBN1
15 menkes disease 33.4 LOX ELN ATP7A
16 occipital horn syndrome 33.3 RIN2 LTBP4 LOX GORAB FBLN5 ELN
17 autosomal recessive cutis laxa type ii classic type 33.2 RIN2 PYCR1 LTBP4 GORAB FBN1 FBLN5
18 geroderma osteodysplasticum 32.5 RIN2 PYCR1 LTBP4 GORAB FBLN5 EFEMP2
19 pulmonary emphysema 31.6 LOX ELN ELANE
20 elastosis perforans serpiginosa 31.4 ELN ABCC6
21 pseudoxanthoma elasticum 31.3 GGCX FBN1 ELN ABCC6
22 arterial tortuosity syndrome 31.2 LTBP4 FBN1 FBLN5 ELN EFEMP2
23 costello syndrome 31.0 LOX FBN1 FBLN5 ELN
24 aortic aneurysm 31.0 LOX FBN1 FBLN5 ELN EFEMP2
25 aortic valve insufficiency 30.9 FBN1 ELN EFEMP2
26 inguinal hernia 30.8 LOXL1 LOX FBN1 FBLN5 ELN ELANE
27 connective tissue disease 30.8 LOX FBN1 FBLN5 ELN ATP7A ABCC6
28 supravalvular aortic stenosis 30.8 LAMB1 FBN1 FBLN5 ELN EFEMP2
29 tricuspid valve prolapse 30.7 FBN1 FBLN5 EFEMP2
30 angioid streaks 30.7 GGCX ELN ABCC6
31 pneumothorax 30.6 FBN1 FBLN5 ELN
32 aneurysm 30.6 LOX FBN1 ELN
33 aortic aneurysm, familial thoracic 1 30.4 LOX FBN1 FBLN5 ELN EFEMP2
34 blepharochalasis 30.4 GSN ELN
35 aortic disease 30.4 LOX FBN1 ELN
36 scoliosis 30.3 RIN2 LTBP4 LOXL1 LOX FBN1 FBLN5
37 diaphragmatic eventration 30.0 LTBP4 FBN1
38 cutis laxa, autosomal dominant 2 12.9
39 cutis laxa, autosomal recessive, type iic 12.9
40 cutis laxa, autosomal dominant 3 12.9
41 efemp2-related cutis laxa 12.6
42 cutis laxa, neonatal, with marfanoid phenotype 12.6
43 atp6v0a2-related cutis laxa 12.6
44 ltbp4-related cutis laxa 12.6
45 autosomal recessive cutis laxa type 2 12.5
46 dysmorphism cleft palate loose skin 12.4
47 cutis laxa osteoporosis 12.4
48 scarf syndrome 12.3
49 lenz-majewski hyperostotic dwarfism 11.8
50 transaldolase deficiency 11.8

Graphical network of the top 20 diseases related to Cutis Laxa:



Diseases related to Cutis Laxa
Sources

Symptoms & Phenotypes for Cutis Laxa

About this section

Human phenotypes related to Cutis Laxa:

58 31 (show top 50) (show all 73)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 inguinal hernia 58 31 hallmark (90%) Very frequent (99-80%) HP:0000023
2 short stature 58 31 hallmark (90%) Very frequent (99-80%) HP:0004322
3 abnormality of retinal pigmentation 58 31 hallmark (90%) Very frequent (99-80%) HP:0007703
4 aplasia/hypoplasia of the abdominal wall musculature 58 31 hallmark (90%) Very frequent (99-80%) HP:0010318
5 lack of skin elasticity 58 31 hallmark (90%) Very frequent (99-80%) HP:0100679
6 patent ductus arteriosus 58 31 hallmark (90%) Very frequent (99-80%) HP:0001643
7 redundant skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0001582
8 excessive wrinkled skin 58 31 hallmark (90%) Very frequent (99-80%) HP:0007392
9 bowel diverticulosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0005222
10 esophageal diverticulum 58 31 hallmark (90%) Very frequent (99-80%) HP:0100628
11 global developmental delay 58 31 frequent (33%) Frequent (79-30%) HP:0001263
12 muscular hypotonia 58 31 frequent (33%) Frequent (79-30%) HP:0001252
13 scoliosis 58 31 frequent (33%) Frequent (79-30%) HP:0002650
14 recurrent respiratory infections 58 31 frequent (33%) Frequent (79-30%) HP:0002205
15 carious teeth 58 31 frequent (33%) Frequent (79-30%) HP:0000670
16 malabsorption 58 31 frequent (33%) Frequent (79-30%) HP:0002024
17 short nose 58 31 frequent (33%) Frequent (79-30%) HP:0003196
18 hydrocephalus 58 31 frequent (33%) Frequent (79-30%) HP:0000238
19 muscle weakness 58 31 frequent (33%) Frequent (79-30%) HP:0001324
20 prominent forehead 58 31 frequent (33%) Frequent (79-30%) HP:0011220
21 abnormality of the hip bone 58 31 frequent (33%) Frequent (79-30%) HP:0003272
22 recurrent urinary tract infections 58 31 frequent (33%) Frequent (79-30%) HP:0000010
23 narrow mouth 58 31 frequent (33%) Frequent (79-30%) HP:0000160
24 joint dislocation 58 31 frequent (33%) Frequent (79-30%) HP:0001373
25 bowel incontinence 58 31 frequent (33%) Frequent (79-30%) HP:0002607
26 intrauterine growth retardation 58 31 frequent (33%) Frequent (79-30%) HP:0001511
27 micrognathia 58 31 frequent (33%) Frequent (79-30%) HP:0000347
28 low-set ears 58 31 frequent (33%) Frequent (79-30%) HP:0000369
29 thickened nuchal skin fold 58 31 frequent (33%) Frequent (79-30%) HP:0000474
30 epicanthus 58 31 frequent (33%) Frequent (79-30%) HP:0000286
31 ptosis 58 31 frequent (33%) Frequent (79-30%) HP:0000508
32 pectus excavatum 58 31 frequent (33%) Frequent (79-30%) HP:0000767
33 depressed nasal ridge 58 31 frequent (33%) Frequent (79-30%) HP:0000457
34 vesicoureteral reflux 58 31 frequent (33%) Frequent (79-30%) HP:0000076
35 long philtrum 58 31 frequent (33%) Frequent (79-30%) HP:0000343
36 turricephaly 58 31 frequent (33%) Frequent (79-30%) HP:0000262
37 telecanthus 58 31 frequent (33%) Frequent (79-30%) HP:0000506
38 large fontanelles 58 31 frequent (33%) Frequent (79-30%) HP:0000239
39 plagiocephaly 58 31 frequent (33%) Frequent (79-30%) HP:0001357
40 hydroureter 58 31 frequent (33%) Frequent (79-30%) HP:0000072
41 ectopic anus 58 31 frequent (33%) Frequent (79-30%) HP:0004397
42 abnormal palate morphology 58 31 frequent (33%) Frequent (79-30%) HP:0000174
43 aplasia/hypoplasia of the tongue 58 31 frequent (33%) Frequent (79-30%) HP:0010295
44 bronchiectasis 58 31 frequent (33%) Frequent (79-30%) HP:0002110
45 genital hernia 58 31 frequent (33%) Frequent (79-30%) HP:0100823
46 hypertelorism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000316
47 short neck 58 31 occasional (7.5%) Occasional (29-5%) HP:0000470
48 pectus carinatum 58 31 occasional (7.5%) Occasional (29-5%) HP:0000768
49 anteverted nares 58 31 occasional (7.5%) Occasional (29-5%) HP:0000463
50 hypothyroidism 58 31 occasional (7.5%) Occasional (29-5%) HP:0000821

UMLS symptoms related to Cutis Laxa:


pruritus

GenomeRNAi Phenotypes related to Cutis Laxa according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.68 GSN
2 Decreased viability GR00055-A-2 9.68 GSN
3 Decreased viability GR00055-A-3 9.68 GSN
4 Decreased viability GR00240-S-1 9.68 GGCX
5 Decreased viability GR00249-S 9.68 ATP7A EFEMP2 GORAB
6 Decreased viability GR00386-A-1 9.68 ATP6V1A ATP7A EFEMP2 ELN GORAB LOXL1
7 Decreased viability GR00402-S-2 9.68 ABCC6 ALDH18A1 ATP6V0A2 ATP6V1A EFEMP2 ELN

MGI Mouse Phenotypes related to Cutis Laxa:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.03 ABCC6 ATP7A ELANE FBLN5 FBN1 GGCX
2 integument MP:0010771 9.97 ABCC6 ALDH18A1 ATP6V0A2 ATP7A EFEMP2 ELANE
3 muscle MP:0005369 9.5 ATP7A EFEMP2 FBLN5 FBN1 LAMB1 LOX
4 respiratory system MP:0005388 9.28 ATP7A EFEMP2 FBLN5 FBN1 GORAB GSN
Sources

Drugs & Therapeutics for Cutis Laxa

About this section

Drugs for Cutis Laxa (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Phylloquinone Approved, Investigational Phase 4 84-80-0
2 fluindione Approved, Investigational Phase 4 957-56-2
3
Warfarin Approved Phase 4 81-81-2 6691 54678486
4
Dalteparin Approved Phase 4 9005-49-6
5
Phenindione Approved, Investigational Phase 4 83-12-5 4760
6
Rivaroxaban Approved Phase 4 366789-02-8
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
9 Menaquinone Investigational Phase 4 1182-68-9
10 Antithrombins Phase 4
11 Vitamins Phase 4
12 Antithrombin III Phase 4
13 Serine Proteinase Inhibitors Phase 4
14 Factor Xa Inhibitors Phase 4
15
protease inhibitors Phase 4
16 Heparin, Low-Molecular-Weight Phase 4
17 HIV Protease Inhibitors Phase 4
18 Antivitamins K Phase 4
19 Anticoagulants Phase 4
20 Vitamin K Phase 4
21 naphthoquinone Phase 4
22 Sodium Channel Blockers Phase 4
23 Anesthetics Phase 4
24 Anti-Arrhythmia Agents Phase 4
25 Diuretics, Potassium Sparing Phase 4
26 Anesthetics, Local Phase 4
27
Serine Investigational, Nutraceutical Phase 4 56-45-1 5951
28 Carotenoids Phase 3
29 Hormones Phase 1
30 Calcium, Dietary Phase 1
31
Calcium Nutraceutical Phase 1 7440-70-2 271
32
Bimatoprost Approved, Investigational Early Phase 1 155206-00-1 5311027
33
Ibuprofen Approved 15687-27-1 3672
34
Mannitol Approved, Investigational 69-65-8 6251 453
35
Hyaluronic acid Approved, Vet_approved 9004-61-9 53477741
36 Antihypertensive Agents Early Phase 1
37 Ophthalmic Solutions Early Phase 1
38 Acetaminophen, hydrocodone drug combination
39 Analgesics
40 diuretics
41 Dermatologic Agents
42 Deuterium Oxide
43 Radiation-Protective Agents
44 Pharmaceutical Solutions
45 Viscosupplements
46 Adjuvants, Immunologic
47 Protective Agents
48 Immunologic Factors
49 incobotulinumtoxinA

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Suture Granuloma in Body Contouring Surgery Completed NCT00223132 Phase 4
2 The VICTORIA Study (Vascular CalcIfiCation and sTiffness Induced by ORal antIcoAgulation) Comparison Anti-vitamin K Versus Anti-Xa. Completed NCT02161965 Phase 4 Rivaroxaban;Fluindione;Warfarin
3 Vibration-Assisted Anaesthesia: A Randomised Controlled Trial to Investigate Whether Vibration Reduces the Pain of Anaesthetic Injection in Eyelid Surgery Completed NCT00793988 Phase 4
4 A Prospective Study Evaluating the Effectiveness of Juvederm Volift With Lidocaine for Treatment of the Aging Hands Not yet recruiting NCT04390581 Phase 4
5 The Derm Aid Study Recruiting NCT04249128 Phase 3
6 Evaluation the Safety and Efficacy of the Treatment of Scars and Cutis Laxa Syndrome With the Use of Autologous (Fresh and Stored) Stem Cells Isolated From Adipose Tissue. Completed NCT03887208 Phase 1, Phase 2
7 Safety and Efficacy of SofWave Treatment to Lift Lax Tissue in the Submental and Neck Zones and to Lift the Eyebrow Recruiting NCT04146584 Phase 2
8 Combined Focused Ultrasound and Calcium Hydroxylapatitie Filler for Skin Laxity Recruiting NCT04176068 Phase 1
9 A Prospective, Multi-center, Pivotal Study to Evaluate the Safety and Efficacy of a Micro-Coring Device for the Treatment of Moderate to Severe Facial Wrinkles Unknown status NCT03573271
10 Evaluation of Ocular Surface Changes Following RF Electrocoagulation Treatment of the Periorbital Region Unknown status NCT03280069
11 Topical Bimatoprost for Chemical Blepharoplasty Unknown status NCT02830776 Early Phase 1 bimatoprost 0.03% ophthalmic solution
12 The Prevalence of Dry Eye Syndrome Among Patients Who Underwent Upper Eyelids Blepharoplasty With and Without Muller Muscle Resection Completed NCT02376556
13 TP-1013 Pilot 1: Application of the Apsara Thermal Wand System Completed NCT00662389 Early Phase 1
14 Clinical Study on the Application of a Non-Invasive Micro-Focused Ultrasound With Visualization System for Skin Laxity Completed NCT03545412
15 Randomized-controlled Split-face Treatment of Facial Rhytids and Laxity in Asians Using Long-pulse 1064nm Laser Completed NCT01971736
16 Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Completed NCT01368874
17 Open-label, Prospective Evaluation of the Ulthera® System for Lifting Submental (Under the Chin) and Neck Tissue in Chinese Patients Completed NCT03351335
18 Efficacy and Tolerance Evaluation of an Antiage Aesthetic Treatment for the Middle and Inferior Third of the Face Completed NCT04239768
19 Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity in Patients With Fitzpatrick Skin Phototypes 3 Through 6 Completed NCT01368965
20 Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck With Lower Energy Settings Completed NCT01713998
21 Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of Facial and Neck Skin Laxity Using a Customized, High-Density and Vectoring Treatment Approach Completed NCT01708512
22 Feasibility Study: Evaluation of the Ulthera® System for Efficacious and Safe Treatment of Laxity/Crepiness and Texture of Abdominal Tissue Completed NCT01708499
23 Feasibility Study: Comparison Of Advil® Vs. Lortab® For Reducing Discomfort Associated With Ultherapyâ„¢ Treatment Completed NCT01708473 Advil;Lortab
24 Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening the Buttocks and Thighs Completed NCT01708460
25 Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Knees Completed NCT01708434
26 Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Elbow Tissue - A Feasibility Study Completed NCT01708382
27 Retrospective Evaluation of the Ulthera System for Lifting and Tightening of the Face and Neck Completed NCT01519934
28 Evaluation of the Efficacy and Safety of the Ulthera® System for Lifting and Tightening of the Face and Neck Following an Increased Density Treatment. Completed NCT01519206
29 Feasibility Study: Evaluation of the Ulthera® System for Lifting and Tightening of the Décolleté Completed NCT01485107
30 Evaluation of the Ulthera® System and Efficacy Correlation to Morphological Differences Completed NCT03599349
31 A Prospective, Multi-center, Randomized Pilot Study for the Safety and Efficacy of a GEN II Micro-coring Device for the Treatment of Wrinkles and Skin Laxity in the Pre-auricular Area and Mid to Lower Face Completed NCT03228641
32 Retrospective Evaluation of Safety of Combination Treatment With the Ulthera® System and Xeomin, Belotero Balance, and Radiesse Completed NCT02444169 Incobotulinumtoxin A
33 A Randomized, Split-body Clinical Trial of Poly-L-lactic Acid (Sculptra Aesthetic) for the Treatment of Upper Knee Skin Laxity Completed NCT03487172
34 Evaluation of the Ultheraâ„¢ System For Obtaining Lift and Tightening of the Cheek Tissue and Improvement in Jawline Definition and Submental Skin Laxity Completed NCT01368835
35 Feasibility Study: Evaluation of the Ulthera® System vs Thermage® for Lifting and Tightening of the Full Face and Neck Completed NCT01713985
36 Feasibility Study: Evaluation Of The Ultheraâ„¢ System For Obtaining Lift And Tightening Of The Neck Skin In Patients With A History Of Submentoplasty And Or Rhytidectomy Vs Patients Naïve To Submentoplasty Or Rhytidectomy - A Feasibility Study Completed NCT01708928
37 Feasibility Study: Evaluation of the Efficacy of a Liposome-encapsulated Lidocaine Topical Anesthetic for Reducing Discomfort Associated With Ultherapyâ„¢ Treatment Completed NCT01708447 L.M.X.4.® cream
38 Feasibility Study: Evaluation of the Ulthera® System for Obtaining Lift and Tightening of the Neck in Post-Surgery and Surgery Naive Patients Who Failed to Respond to a Previous Ultherapyâ„¢ Treatment Completed NCT01708252
39 Exploratory Evaluation of the Lutronic Genius System for Treatment of the Neck Completed NCT03534609
40 Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Following Sculptra® Treatment Completed NCT01422538 Sculptra®
41 Evaluation of the Ulthera® System for Lifting and Tightening the Face and Neck Using Standard Transducers Versus Simulines Transducers Completed NCT02416076
42 Clinical Evaluation of the Safety and Efficacy of Using Multi-Polar Radio Frequency and Pulsed Electromagnetic Field Therapy Technologies for the Treatment of the Mon Pubis, Vaginal Introitus and Labia Skin Laxity Completed NCT02770287
43 Feasibility Study: Determination of the Effect of Ultherapy® Treatment on the Rate of Collagen Synthesis in Normal Skin Completed NCT01708525
44 A Prospective, Multi-center, Pilot Study to Evaluate the Efficacy of Micro-Excisional Skin Remodeling With Micro-Coring Device in the Treatment of Wrinkles and Skin Laxity of Face and Neck Completed NCT03583918
45 Use of 2 Octyl-cyanoacrylate Together With a Self-adhering Mesh for Skin Closure Following Abdominoplasty: An Open, Prospective, Controlled, Randomized Clinical Study Completed NCT01658163
46 The CONFORM Study: A Multi-center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring Completed NCT03407313
47 Pilot Study: Clinical Assessment of Bipolar Radiofrequency Microneedling for Improved Laxity and Wrinkles of the Suprapatellar Skin Completed NCT03507036
48 An Open-Label, Single-Center, Single-Treatment, Safety and Effectiveness Evaluation of Percutaneous Radiofrequency in Achieving Submental Lift Completed NCT02832674
49 The PREFORM Study: An Exploratory, Single-Center Study to Evaluate the Safety and Efficacy of Rotational Fractional Resection on Submental Contouring and Optimal Peri-Procedure Regimen for Accelerated Recovery Completed NCT03966924
50 Pathogenetic Basis of Aortopathy and Aortic Valve Disease Recruiting NCT03440697

Search NIH Clinical Center for Cutis Laxa

Cochrane evidence based reviews: cutis laxa

Sources

Genetic Tests for Cutis Laxa

About this section

Genetic tests related to Cutis Laxa:

# Genetic test Affiliating Genes
1 Cutis Laxa 29
Sources

Anatomical Context for Cutis Laxa

About this section

MalaCards organs/tissues related to Cutis Laxa:

40
Skin, Heart, Lung, Bone, Eye, Tongue, Neutrophil
Sources

Publications for Cutis Laxa

About this section

Articles related to Cutis Laxa:

(show top 50) (show all 753)
# Title Authors PMID Year
1
Structural effects of fibulin 5 missense mutations associated with age-related macular degeneration and cutis laxa. 54 61
20007835 2010
2
Hereditary gelsolin amyloidosis mimicking Sjögren's syndrome. 61 54
19701715 2009
3
Fibulin 5 forms a compact dimer in physiological solutions. 61 54
19617354 2009
4
Autosomal recessive cutis laxa syndrome revisited. 54 61
19401719 2009
5
Lethal cutis laxa with contractural arachnodactyly, overgrowth and soft tissue bleeding due to a novel homozygous fibulin-4 gene mutation. 61 54
19664000 2009
6
An autosomal-recessive form of cutis laxa is due to homozygous elastin mutations, and the phenotype may be modified by a heterozygous fibulin 5 polymorphism. 54 61
19194475 2009
7
A p.C217R mutation in fibulin-5 from cutis laxa patients is associated with incomplete extracellular matrix formation in a skin equivalent model. 54 61
18185537 2008
8
Highly variable cutis laxa resulting from a dominant splicing mutation of the elastin gene. 54 61
18348261 2008
9
Association of cutis laxa and genital prolapse: a case report. 54 61
17453126 2007
10
Fibulin-5 mutations: mechanisms of impaired elastic fiber formation in recessive cutis laxa. 54 61
17035250 2006
11
Elastic fibres in health and disease. 61 54
16893474 2006
12
Homozygous missense mutation in fibulin-5 in an Iranian autosomal recessive cutis laxa pedigree and associated haplotype. 61 54
16691202 2006
13
Reduced secretion of fibulin 5 in age-related macular degeneration and cutis laxa. 61 54
16652333 2006
14
Aortic aneurysmal disease and cutis laxa caused by defects in the elastin gene. 54 61
16085695 2006
15
Inflammatory destruction of elastic fibers in acquired cutis laxa is associated with missense alleles in the elastin and fibulin-5 genes. 54 61
16374472 2006
16
Congenital heart disease: Molecular diagnostics of supravalvular aortic stenosis. 54 61
16930010 2006
17
Autosomal dominant cutis laxa with severe lung disease: synthesis and matrix deposition of mutant tropoelastin. 54 61
15955094 2005
18
A combined defect in the biosynthesis of N- and O-glycans in patients with cutis laxa and neurological involvement: the biochemical characteristics. 61 54
15955459 2005
19
[Localized acquired cutis laxa associated with trachyonychia]. 54 61
16476396 2005
20
Cutis laxa in hereditary gelsolin amyloidosis. 61 54
15727635 2005
21
Cutis laxa of the autosomal recessive type in a consanguineous family. 54 61
14721770 2003
22
Genetic heterogeneity of cutis laxa: a heterozygous tandem duplication within the fibulin-5 (FBLN5) gene. 61 54
12618961 2003
23
Homozygosity for a missense mutation in fibulin-5 (FBLN5) results in a severe form of cutis laxa. 54 61
12189163 2002
24
Cutis laxa and pulmonary emphysema. 61 54
18610669 2001
25
Williams syndrome and related disorders. 61 54
11701637 2000
26
Cutis laxa arising from frameshift mutations in exon 30 of the elastin gene (ELN). 61 54
9873040 1999
27
An elastin gene mutation producing abnormal tropoelastin and abnormal elastic fibres in a patient with autosomal dominant cutis laxa. 54 61
9580666 1998
28
Congenital cutis laxa and lysyl oxidase deficiency. 61 54
9111998 1997
29
Cutis laxa acquisita associated with multiple myeloma: a case report and review of the literature. 61 54
8727781 1996
30
Sweet's syndrome leading to acquired cutis laxa (Marshall's syndrome) in an infant with alpha 1-antitrypsin deficiency. 54 61
7574835 1995
31
Transforming growth factor-beta reverses a posttranscriptional defect in elastin synthesis in a cutis laxa skin fibroblast strain. 54 61
7884000 1995
32
Regulation of elastin synthesis in pathological states. 61 54
8575269 1995
33
Elastin production and degradation in cutis laxa acquisita. 61 54
7930686 1994
34
Abnormalities of fibrillin in acquired cutis laxa. 61 54
8188885 1994
35
Aging of the skin connective tissue: how to measure the biochemical and mechanical properties of aging dermis. 61 54
8043384 1994
36
First report of de novo 12q14.2-q23.3 duplication: patient with multiple congenital anomalies, neurodevelopmental delay, and a connective tissue disorder-like phenotype including cutis laxa. 61
32141891 2020
37
Identification of a Novel 19-bp Deletion Mutation in LTBP4 Using Exome Sequencing in Two Siblings with Autosomal Recessive Cutis Laxa Type 1C. 61
32341818 2020
38
Severe elastolysis in hereditary gelsolin (AGel) amyloidosis. 61
31814469 2020
39
Novel defect in phosphatidylinositol 4-kinase type 2-alpha (PI4K2A) at the membrane-enzyme interface is associated with metabolic cutis laxa. 61
32418222 2020
40
Molecular Genetics and Pathogenesis of Ehlers-Danlos Syndrome and Related Connective Tissue Disorders. 61
32414079 2020
41
Lysyl Oxidase Like 1: Biological roles and regulation. 61
32070696 2020
42
Biallelic variants in EFEMP1 in a man with a pronounced connective tissue phenotype. 61
31792352 2020
43
Acquired Cutis Laxa. 61
32329984 2020
44
A rare case of bladder diverticulosis. 61
32353716 2020
45
An incidental finding in newborn screening leading to the diagnosis of a patient with ECHS1 mutations. 61
31908952 2020
46
Expanding the Spectrum of Neurological Manifestations in Cutis Laxa, Autosomal Recessive, Type IIIA. 61
32143220 2020
47
Δ1 -Pyrroline-5-carboxylate synthetase deficiency: An emergent multifaceted urea cycle-related disorder. 61
32017139 2020
48
Acquired cutis laxa secondary to Sweet syndrome in a child (Marshall syndrome): A rare case report. 61
31437319 2020
49
The Earliest Illustration of Cutis Laxa Macroscopic Pattern in Jan van Eyck's Lucca Madonna. 61
32043334 2020
50
Generalized Acquired Cutis Laxa Associated with Monoclonal Gammopathy of Dermatological Significance. 61
32099688 2020
Sources

Variations for Cutis Laxa

About this section

ClinVar genetic disease variations for Cutis Laxa:

6 (show top 50) (show all 105) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 ABCC6 NM_001171.5(ABCC6):c.3421C>T (p.Arg1141Ter)SNV Pathogenic 6559 rs72653706 16:16256935-16256935 16:16163078-16163078
2 PYCR1 NM_006907.4(PYCR1):c.797G>A (p.Arg266Gln)SNV Pathogenic 13190 rs121918374 17:79892202-79892202 17:81934326-81934326
3 PYCR1 NM_006907.4(PYCR1):c.633+1G>CSNV Pathogenic/Likely pathogenic 325904 rs144346996 17:79892528-79892528 17:81934652-81934652
4 COL5A1 NM_001278074.1(COL5A1):c.2903del (p.Pro968fs)deletion Likely pathogenic 374067 rs1057518871 9:137690256-137690256 9:134798410-134798410
5 FAM120AOS NM_198841.4(FAM120AOS):c.743C>T (p.Thr248Ile)SNV Likely pathogenic 183343 rs140119177 9:96209921-96209921 9:93447639-93447639
6 SLC39A13 NM_001128225.3(SLC39A13):c.398C>T (p.Thr133Met)SNV Conflicting interpretations of pathogenicity 196579 rs140574574 11:47433573-47433573 11:47412022-47412022
7 FBLN5 NM_006329.3(FBLN5):c.268G>A (p.Gly90Ser)SNV Conflicting interpretations of pathogenicity 218359 rs144288844 14:92403402-92403402 14:91937058-91937058
8 FBLN5 NM_006329.3(FBLN5):c.376G>A (p.Val126Met)SNV Conflicting interpretations of pathogenicity 218360 rs61734479 14:92403294-92403294 14:91936950-91936950
9 FBLN5 NM_006329.3(FBLN5):c.604G>A (p.Gly202Arg)SNV Conflicting interpretations of pathogenicity 21453 rs80338765 14:92357580-92357580 14:91891236-91891236
10 FBLN5 NM_006329.3(FBLN5):c.1241G>A (p.Arg414Gln)SNV Conflicting interpretations of pathogenicity 885290 14:92336674-92336674 14:91870330-91870330
11 FBLN5 NM_006329.3(FBLN5):c.273G>A (p.Pro91=)SNV Conflicting interpretations of pathogenicity 887258 14:92403397-92403397 14:91937053-91937053
12 PYCR1 NM_006907.4(PYCR1):c.615C>T (p.Leu205=)SNV Conflicting interpretations of pathogenicity 678602 17:79892547-79892547 17:81934671-81934671
13 PYCR1 NM_006907.4(PYCR1):c.334C>T (p.Arg112Trp)SNV Conflicting interpretations of pathogenicity 282265 rs147653673 17:79893008-79893008 17:81935132-81935132
14 FBLN5 NM_006329.3(FBLN5):c.621T>C (p.Asp207=)SNV Conflicting interpretations of pathogenicity 287193 rs200178859 14:92353655-92353655 14:91887311-91887311
15 FBLN5 NM_006329.3(FBLN5):c.1191G>A (p.Thr397=)SNV Conflicting interpretations of pathogenicity 314871 rs148660796 14:92336724-92336724 14:91870380-91870380
16 FBLN5 NM_006329.3(FBLN5):c.862+12C>TSNV Conflicting interpretations of pathogenicity 314875 rs202088447 14:92349286-92349286 14:91882942-91882942
17 FBLN5 NM_006329.3(FBLN5):c.676G>A (p.Gly226Ser)SNV Conflicting interpretations of pathogenicity 314877 rs747288805 14:92353600-92353600 14:91887256-91887256
18 FBLN5 NM_006329.3(FBLN5):c.989+9C>TSNV Conflicting interpretations of pathogenicity 314874 rs557362799 14:92347627-92347627 14:91881283-91881283
19 FBLN5 NM_006329.3(FBLN5):c.*648G>ASNV Conflicting interpretations of pathogenicity 314861 rs182435130 14:92335920-92335920 14:91869576-91869576
20 PYCR1 NM_006907.4(PYCR1):c.285C>T (p.Cys95=)SNV Conflicting interpretations of pathogenicity 325910 rs113491328 17:79893246-79893246 17:81935370-81935370
21 PYCR1 NM_006907.4(PYCR1):c.180G>A (p.Val60=)SNV Conflicting interpretations of pathogenicity 325912 rs142458410 17:79893351-79893351 17:81935475-81935475
22 PYCR1 NM_006907.4(PYCR1):c.399C>T (p.Thr133=)SNV Conflicting interpretations of pathogenicity 325908 rs148883988 17:79892943-79892943 17:81935067-81935067
23 PYCR1 NM_006907.4(PYCR1):c.261G>A (p.Glu87=)SNV Conflicting interpretations of pathogenicity 325911 rs138261889 17:79893270-79893270 17:81935394-81935394
24 PYCR1 NM_006907.4(PYCR1):c.110T>G (p.Met37Arg)SNV Uncertain significance 325917 rs138792258 17:79894027-79894027 17:81936151-81936151
25 PYCR1 NM_006907.4(PYCR1):c.*699G>TSNV Uncertain significance 325893 rs886053567 17:79890391-79890391 17:81932515-81932515
26 PYCR1 NM_006907.4(PYCR1):c.*482G>ASNV Uncertain significance 325896 rs570757755 17:79890608-79890608 17:81932732-81932732
27 PYCR1 NM_006907.4(PYCR1):c.-77G>ASNV Uncertain significance 325922 rs886053571 17:79894767-79894767 17:81936891-81936891
28 PYCR1 NM_006907.4(PYCR1):c.-196G>ASNV Uncertain significance 325923 rs764095488 17:79894886-79894886 17:81937010-81937010
29 PYCR1 NM_006907.4(PYCR1):c.*769C>TSNV Uncertain significance 325891 rs545491725 17:79890321-79890321 17:81932445-81932445
30 PYCR1 NM_006907.4(PYCR1):c.*622G>ASNV Uncertain significance 325894 rs886053568 17:79890468-79890468 17:81932592-81932592
31 PYCR1 NM_006907.4(PYCR1):c.*504G>CSNV Uncertain significance 325895 rs886053569 17:79890586-79890586 17:81932710-81932710
32 PYCR1 NM_006907.4(PYCR1):c.*477C>TSNV Uncertain significance 325897 rs539637881 17:79890613-79890613 17:81932737-81932737
33 PYCR1 NM_006907.4(PYCR1):c.*62G>CSNV Uncertain significance 325901 rs566605955 17:79891028-79891028 17:81933152-81933152
34 PYCR1 NM_006907.4(PYCR1):c.176C>T (p.Thr59Met)SNV Uncertain significance 325913 rs150227130 17:79893355-79893355 17:81935479-81935479
35 PYCR1 NM_006907.4(PYCR1):c.768C>T (p.Asn256=)SNV Uncertain significance 325903 rs553609380 17:79892231-79892231 17:81934355-81934355
36 FBLN5 NM_006329.3(FBLN5):c.*775A>CSNV Uncertain significance 314859 rs886050885 14:92335793-92335793 14:91869449-91869449
37 FBLN5 NM_006329.3(FBLN5):c.*653G>ASNV Uncertain significance 314860 rs886050886 14:92335915-92335915 14:91869571-91869571
38 FBLN5 NM_006329.3(FBLN5):c.*98G>ASNV Uncertain significance 314870 rs568348723 14:92336470-92336470 14:91870126-91870126
39 FBLN5 NM_006329.3(FBLN5):c.-139C>TSNV Uncertain significance 314884 rs554315938 14:92413712-92413712 14:91947368-91947368
40 FBLN5 NM_006329.3(FBLN5):c.-389C>ASNV Uncertain significance 314887 rs886050891 14:92413962-92413962 14:91947618-91947618
41 FBLN5 NM_006329.3(FBLN5):c.-428G>CSNV Uncertain significance 314891 rs886050893 14:92414001-92414001 14:91947657-91947657
42 FBLN5 NM_006329.3(FBLN5):c.-382C>GSNV Uncertain significance 314886 rs886050890 14:92413955-92413955 14:91947611-91947611
43 FBLN5 NM_006329.3(FBLN5):c.-413C>TSNV Uncertain significance 314889 rs886050892 14:92413986-92413986 14:91947642-91947642
44 FBLN5 NM_006329.3(FBLN5):c.*458T>CSNV Uncertain significance 314865 rs886050887 14:92336110-92336110 14:91869766-91869766
45 FBLN5 NM_006329.3(FBLN5):c.251A>G (p.Tyr84Cys)SNV Uncertain significance 314880 rs886050889 14:92403419-92403419 14:91937075-91937075
46 PYCR1 NM_006907.4(PYCR1):c.164A>T (p.His55Leu)SNV Uncertain significance 325914 rs777125670 17:79893367-79893367 17:81935491-81935491
47 PYCR1 NM_006907.4(PYCR1):c.-48G>CSNV Uncertain significance 325920 rs376495113 17:79894738-79894738 17:81936862-81936862
48 PYCR1 NM_006907.4(PYCR1):c.-250C>TSNV Uncertain significance 325924 rs886053572 17:79894940-79894940 17:81937064-81937064
49 FBLN5 NM_006329.3(FBLN5):c.*363C>TSNV Uncertain significance 314867 rs536827304 14:92336205-92336205 14:91869861-91869861
50 FBLN5 NM_006329.3(FBLN5):c.388G>A (p.Glu130Lys)SNV Uncertain significance 314879 rs886050888 14:92361408-92361408 14:91895064-91895064
Sources

Expression for Cutis Laxa

About this section
Search GEO for disease gene expression data for Cutis Laxa.
Sources

Pathways for Cutis Laxa

About this section

Pathways related to Cutis Laxa according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Degradation of the extracellular matrix 65
Show member pathways
 12.26 LTBP4 LOXL1 LOX LAMB1 FBN1 FBLN5
2
Ion channel transport 65
Show member pathways
 12.16 ATP7A ATP6V1E1 ATP6V1A ATP6V0A2
3
Synaptic vesicle cycle 36
Show member pathways
 11.69 ATP6V1E1 ATP6V1A ATP6V0A2
4
Rheumatoid arthritis 36
11.4 ATP6V1E1 ATP6V1A ATP6V0A2
5
Elastic fibre formation 65
Show member pathways
 11.03 LTBP4 LOXL1 LOX FBN1 FBLN5 ELN
6
Cell adhesion_Cell-matrix glycoconjugates 22
10.92 LAMB1 ELN ELANE
7
Urea cycle and metabolism of amino groups 1
Show member pathways
 10.81 PYCR1 ALDH18A1
8
G-protein signaling_Rap2B regulation pathway 22
10.62 LTBP4 LAMB1 FBN1 ELN EFEMP2
Sources

GO Terms for Cutis Laxa

About this section

Cellular components related to Cutis Laxa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.07 LTBP4 LOXL1 LOX LAMB1 GSN FBN1
2 cell GO:0005623 9.98 LOX GSN ELANE ATP7A ATP6V1E1 ATP6V1A
3 extracellular space GO:0005615 9.97 LTBP4 LOXL1 LOX LAMB1 GSN FBN1
4 apical plasma membrane GO:0016324 9.78 ATP7A ATP6V1E1 ATP6V1A ABCC6
5 microvillus GO:0005902 9.63 ATP7A ATP6V1E1 ATP6V1A
6 basement membrane GO:0005604 9.46 LOXL1 LAMB1 FBN1 EFEMP2
7 extracellular matrix GO:0031012 9.43 LTBP4 LOXL1 LOX FBN1 FBLN5 ELN
8 proton-transporting two-sector ATPase complex GO:0016469 9.4 ATP6V1E1 ATP6V1A
9 elastic fiber GO:0071953 9.26 FBLN5 ELN
10 collagen-containing extracellular matrix GO:0062023 9.23 LTBP4 LOXL1 LAMB1 FBN1 FBLN5 ELN

Biological processes related to Cutis Laxa according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 ion transmembrane transport GO:0034220 9.81 ATP7A ATP6V1E1 ATP6V1A ATP6V0A2
2 proton transmembrane transport GO:1902600 9.7 ATP6V1E1 ATP6V1A ATP6V0A2
3 insulin receptor signaling pathway GO:0008286 9.67 ATP6V1E1 ATP6V1A ATP6V0A2
4 regulation of macroautophagy GO:0016241 9.65 ATP6V1E1 ATP6V1A ATP6V0A2
5 aorta development GO:0035904 9.55 LOXL1 LOX
6 regulation of transforming growth factor beta receptor signaling pathway GO:0017015 9.54 LTBP4 LOX
7 collagen fibril organization GO:0030199 9.5 LOXL1 LOX ATP7A
8 extracellular matrix organization GO:0030198 9.5 LOXL1 LOX LAMB1 FBN1 FBLN5 ELN
9 L-proline biosynthetic process GO:0055129 9.46 PYCR1 ALDH18A1
10 cellular response to increased oxygen levels GO:0036295 9.43 ATP6V1A ATP6V0A2
11 transferrin transport GO:0033572 9.43 ATP6V1E1 ATP6V1A ATP6V0A2
12 peptidyl-lysine oxidation GO:0018057 9.4 LOXL1 LOX
13 proline biosynthetic process GO:0006561 9.37 PYCR1 ALDH18A1
14 phagosome acidification GO:0090383 9.33 ATP6V1E1 ATP6V1A ATP6V0A2
15 elastic fiber assembly GO:0048251 8.92 LOX FBLN5 EFEMP2 ATP7A

Molecular functions related to Cutis Laxa according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 copper ion binding GO:0005507 9.58 LOXL1 LOX ATP7A
2 integrin binding GO:0005178 9.56 LTBP4 LAMB1 FBN1 FBLN5
3 oxidoreductase activity, acting on the CH-NH2 group of donors, oxygen as acceptor GO:0016641 9.37 LOXL1 LOX
4 proton-transporting ATPase activity, rotational mechanism GO:0046961 9.33 ATP6V1E1 ATP6V1A ATP6V0A2
5 protein-lysine 6-oxidase activity GO:0004720 9.32 LOXL1 LOX
6 extracellular matrix constituent conferring elasticity GO:0030023 9.13 FBN1 FBLN5 ELN
7 extracellular matrix structural constituent GO:0005201 9.02 LTBP4 LAMB1 FBN1 ELN EFEMP2
Sources

Sources for Cutis Laxa

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....